Pooled Efficacy Results From Two Multinational Randomized Controlled Clinical Trials of a Single Intravitreous Injection of Highly Purified Ovine Hyaluronidase (Vitrase®) for the Management of Vitreous Hemorrhage

Kuppermann, Baruch D.; Thomas, Edgar L.; Smet, Marc D. de; Grillone, Lisa R.

doi:10.1016/j.ajo.2005.04.018

Cited by 130 publications

(46 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…, was studied in Phase III trials and showed a significant reduction in vitreous hemorrhage which allowed laser treatment. 36,37 No serious safety issues were reported and the incidence of retinal detachment was not statistically different between treated eyes and control groups. The study did not report on PVD induction.…”

Section: Pegaptanibmentioning

confidence: 95%

Experimental Treatments for Diabetic Macular Edema

Tabandeh¹,

Boyer²

2011

US Ophthalmic Review

View full text Add to dashboard Cite

Diabetic retinopathy remains the most frequent cause of newly diagnosed blindness in the working-age population. This is despite improvements in therapies for blood glucose and blood pressure control, and the many different treatment modalities that are currently available including laser, vitreous surgery, and intravitreal injections.Diabetic macular edema (DME) is the most common reason for loss of reading vision in diabetes patients. After 15 years of known diabetes, DME is present in 20 % of patients with type 1 diabetes mellitus (DM) and in 14 % of patients with type two DM who do not take insulin. DME is present in 30 % of patients who have had diabetes for longer than 20 years. In eyes with mild non-proliferative diabetic retinopathy, the prevalence of DME is 3 %, rising to 38 % in eyes with moderate to severe non-proliferative retinopathy, and to 71 % in eyes with proliferative retinopathy. AbstractDiabetic macular edema (DME) is the most common reason for the loss of reading vision in diabetes patients. Systemic control of blood sugar, blood pressure, and lipids is an important aspect of the management of DME. In these patients, macular laser photocoagulation has been shown to reduce the incidence of moderate visual loss by 50 %. Significant visual improvement occurs in a small minority. Other treatment modalities, such as intravitreal steroids and anti-vascular endothelial growth factor (VEGF) drugs, have become increasingly popular. Case series and small clinical studies are suggestive of a beneficial effect, while large-scale clinical trials are ongoing. Currently, it appears that macular laser photocoagulation remains the gold standard for the treatment of DME. Intravitreal steroids and anti-VEGF agents are useful adjuncts that may improve visual outcomes. Current treatments and ongoing clinical trials are discussed.

show abstract

Section: Pegaptanibmentioning

confidence: 95%

Experimental Treatments for Diabetic Macular Edema

Tabandeh¹,

Boyer²

2011

US Ophthalmic Review

View full text Add to dashboard Cite

show abstract

“…In other studies, it was shown that hyaluronidase and microplasmin reduce the risk of intraocular bleeding. Moreover, positive results of implementing protein kinase C inhibitors were observed impeding the development of diabetic retinopathy [70][71][72][73].…”

Section: Treatment Of Diabetic Retinopathymentioning

confidence: 99%

Diagnosis and treatment of diabetic retinopathy — historical overview

Matuszewski

Bandurska-Stankiewicz

Modzelewski

et al. 2017

Clinical Diabetology

View full text Add to dashboard Cite

show abstract

“…16 In a companion article on the safety results, no serious safety issues were reported. 17 In particular, the incidence of retinal detachment was not statistically different between treated eyes and control groups.…”

Section: Hyaluronidasementioning

confidence: 99%

Enzymatic vitreous disruption

Gandorfer

2008

Eye

View full text Add to dashboard Cite

Enzymatic vitreous disruption refers to cleaving the vitreoretinal junction by enzymatic means, thereby inducing posterior vitreous detachment (PVD) and liquefaction of the vitreous gel. Several enzymes have been proposed in this respect, including chondroitinase, hyaluronidase, dispase, and plasmin. In an experimental setting, chondroitinase induced PVD and was helpful in removing epiretinal membranes but no further data have been reported yet.Hyaluronidase liquefies the vitreous as demonstrated in a phase III trial in diabetic patients with vitreous haemorrhage. Dispase induces PVD but also causes inner retinal damage and is now used as an animal model of proliferative vitreoretinopathy. Plasmin has the capability of both PVD induction and liquefaction. However, plasmin is highly unstable and not available for clinical use. Microplasmin (ThromboGenics Ltd, Dublin, Ireland) is a truncated form of human plasmin sharing the same catalytic activity like plasmin. Recombinant microplasmin is under clinical investigation in patients with vitreomacular traction. This review article reports on the current knowledge of enzymatic vitreous disruption and discusses details of the enzyme candidates in basic and clinical research terms.

show abstract

Pooled Efficacy Results From Two Multinational Randomized Controlled Clinical Trials of a Single Intravitreous Injection of Highly Purified Ovine Hyaluronidase (Vitrase®) for the Management of Vitreous Hemorrhage

Cited by 130 publications

References 20 publications

Experimental Treatments for Diabetic Macular Edema

Experimental Treatments for Diabetic Macular Edema

Diagnosis and treatment of diabetic retinopathy — historical overview

Enzymatic vitreous disruption

Contact Info

Product

Resources

About